U.S., Aug. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07763652) titled 'A Study of BL-ARC002 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors' on Aug. 10.
Brief Summary: This is an open-label, multicenter, non-randomized Phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-ARC002 Injection in patients with locally advanced or metastatic solid tumors.
Study Start Date: Aug., 2026
Study Type: INTERVENTIONAL
Condition:
Gastrointestinal Tumors
Solid Tumors
Intervention:
DRUG: BL-ARC002
Administration by intravenous infusion for a cycle of 6 weeks.
Recruitment Status: NOT_YET_RECRUITIN...